– USA, MA – Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company today announced the appointments of Ellen Chiniara and Dr. Mary Ann Gray, (Ph.D.) to its Board of Directors.
“Ellen and Mary Ann bring immediate and significant value to our board. Ellen’s expertise in strategic advising, mergers and acquisitions, and governance, combined with Mary Ann’s technical know-how and broad experience as a corporate director for biotechs of every stage, are complementary and an ideal fit. We are excited to welcome both to our board at this pivotal time for Compass,” said founder and CEO, Dr. Thomas Schuetz.
Board Chairman, Dr. Carl Gordon said, “The appointments of Ellen and Mary Ann are part of the board’s strategic effort to support Compass as we focus on advancing our promising pipeline through clinical development, driving future growth, and creating additional shareholder value.”
About Ellen Chiniara
Ellen Chiniara was most recently EVP, Chief Legal Officer, and Corporate Secretary of Alexion Pharmaceuticals until its acquisition by AstraZeneca in July 2021. In this role, she was responsible for all legal, intellectual property, and governance matters, and was the executive sponsor of the Corporate Social Responsibility program. Before joining Alexion, Ms. Chiniara was General Counsel of Alere, a point-of-care diagnostics company acquired by Abbott Laboratories in 2017, where she spent over a decade managing various legal and governance functions culminating as the SVP and General Counsel, Chief Ethics & Compliance Officer, and Corporate Secretary of the board. Earlier in her career, she was a partner at the law firm Hale and Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP).
About Dr. Mary Ann Gray
Dr. Mary Ann Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. She currently serves on the boards of five public biotechnology companies: BioAtla, Keros Pharmaceuticals, Palisade Bio, Rapt Therapeutics, and Sarepta Pharmaceuticals. Previously, Dr. Gray served as a Senior Analyst and Portfolio Manager of Federated Kaufmann Fund. Earlier in her career, she was a biotechnology equity research analyst at multiple firms, as well as a senior scientist in the pharmaceutical industry.
Dr. Gray has a Ph.D. in Pharmacology from the University of Vermont, where she focused on novel chemotherapeutic agents for the treatment of cancer. She did post-doctoral work at Northwestern University Medical School and Yale University School of Medicine.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
For more information: https://www.compasstherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
